India’s central health problem is reach. Where good care exists and can be paid for, it is often very good. The failure is that too many people live far from a trained clinician, a working diagnostic lab or a hospital bed that will take their insurance. Technology adds value only on top of a physical network of clinics, labs, doctors and beds, and the network is the harder thing to build.
Where the gaps are physical
Start with primary care, the first contact where most conditions can be caught early. In much of the country that contact is an informal provider or an overcrowded public facility. The government’s response has been to upgrade sub-centres and primary health centres into Health and Wellness Centres, now called Ayushman Arogya Mandirs, which screen for common non-communicable diseases and offer a wider set of services. Their value depends on a plain question: is a trained provider present, with drugs and tests in stock, on the day a patient walks in?
Diagnostics are the next break. A scan or a pathology test is often the step at which a patient is lost, because labs and radiology cluster in cities and large towns, and the specialist who reads a scan may be far from the machine that took it. Specialists are concentrated the same way. Oncologists, cardiologists and neurologists practise mostly in a few cities, so patients travel, lose wages and arrive later than they should.
Teleconsultation helps with some of this. The government’s eSanjeevani service lets a patient at a health centre consult a doctor elsewhere. But a video call cannot take a biopsy or perform a procedure. Telemedicine moves information across distance. It does not move equipment or hands.
Insurance and records: demand and plumbing
Ayushman Bharat PM-JAY, launched in 2018, gives eligible families cashless hospitalisation at empanelled public and private hospitals. The National Health Authority and state agencies act as purchasers, buying care from providers. It is a design for demand, and it does reduce the financial shock of a hospital stay. It mainly covers inpatient care, though, and a card is worth little in a district with few empanelled hospitals. Insurance of this kind tends to pull private capital toward cities where it was already going.
Here is a position that some will dispute. Coverage design should now pay as much attention to supply as to demand. Package rates that make it viable to run a compact hospital in a mid-sized town, even if that means rates that differ by location, will do more for access than another round of enrolment. Reimbursement is a signal about where to build.
The Ayushman Bharat Digital Mission works on the plumbing. It provides a health account number known as ABHA, registries of health facilities and professionals, and consent-based sharing of records on open specifications, in the same spirit as India’s other public digital rails. The promise is that a patient’s history follows her from a village clinic to a city hospital. The limit is equally plain. A record exists only if a clinic wrote it down in the first place, and a registry lists only those facilities that sign up.
A health record is only as useful as the clinic that writes it and the lab that reads it.
Where capital and operators should look
The businesses most worth building add physical capacity where it is thin. Examples include diagnostic networks with hub-and-spoke labs and dependable sample logistics, compact hospitals in mid-sized towns, and specialist services that can be run to shared protocols, such as dialysis, day-care oncology and imaging with remote reporting. Technology belongs inside these models, not ahead of them. Remote reporting is valuable because someone has bought and installed the scanner.
Primary care operators that write records into the digital mission’s formats from day one are a natural fit, because they create the data that the rest of the system assumes already exists. Operators in these areas will also find that the hard parts are unglamorous: recruiting and retaining clinicians outside metros, keeping drug and consumable supply reliable, and handling payments from public schemes on time.
Pharmaceutical and medical-device manufacturing is a separate story, and it should be kept separate. India is among the largest suppliers of generic medicines to the world, and the government has used production-linked incentive schemes for pharmaceuticals and for medical devices to deepen domestic manufacturing, including of inputs that are now largely imported. That is an industrial-policy question about cost, quality and dependence. It should not be mistaken for a fix to access. A country can make excellent drugs and still have patients who cannot get a diagnosis.
What we are watching is whether PM-JAY packages and digital mission adoption actually produce hospitals and labs in towns that lack them, or simply reorganise where existing capacity is billed. The open problem underneath is people. Doctors, nurses and technicians are the binding constraint on every model described here, and no scheme or software has yet solved how to place and keep them outside the largest cities.